We are live on ! Find out more
GDTC icon

CytoMed Therapeutics
GDTC

2 hedge funds and large institutions have $98.5K invested in CytoMed Therapeutics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $70.3K → $98.5K (+$28.2K)

0.09% more ownership

Funds ownership: 0.27% → 0.36% (+0.09%)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$23.7K
2
UBS Group
UBS Group
Switzerland
+$7.14K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$58.9K +$23.7K +10,419 +60%
UBS Group
2
UBS Group
Switzerland
$39.6K +$7.14K +3,134 +22%

GDTC Hedge Fund Activity: Q2 2025 in Review

2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q2 2025, worth a combined $98.5K — up 40% from $70.3K a quarter earlier.

Fund positioning in GDTC was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $23.7K.

  • 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $98.5K of CytoMed Therapeutics stock for Q2 2025, up 40% quarter-over-quarter.
  • 0 funds opened new CytoMed Therapeutics positions in Q2 2025 and 0 closed out.
  • The largest CytoMed Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $23.7K added.

Based on aggregated 13F filings for Q2 2025.